Glenmede Trust Company »

Celldex Therapeutics shares owned by Glenmede Trust Company

Quarter-by-quarter ownership of Celldex Therapeutics (CLDX) shares owned by Glenmede Trust Company from 13F filings

Historical chart of Glenmede Trust Company investment in Celldex Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Celldex Therapeutics held by Glenmede Trust Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Celldex Therapeutics by Glenmede Trust Company

Quarter filed Position value Share count Share price at filing
2026-03-31 $357k 11k 31.72

More positions owned by Glenmede Trust Company

Vanguard Index Fds S&p 500 Etf S&p 500 Etf Shs (VOO)
Apple (AAPL)
Ishares S & P Smallcap 600 Core S&p Scp Etf (IJR)
Microsoft Corporation (MSFT)
Call On Spy 12/18/26 @ 680 Tr Unit Call Option (SPY)
Alphabet Inc Cap Stk Cl A Cap Stk Cl A (GOOGL)
Johnson & Johnson (JNJ)
JPMorgan Chase & Co. (JPM)
Ishares Russell 2500 Etf Rusel 2500 Etf (SMMD)
Putnam Focused Large Cap Value Etf Focused Lar Cap (PVAL)
Alphabet Inc Cap Stk Cl C Cap Stk Cl C (GOOG)
Eli Lilly & Co. (LLY)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Vanguard Index Fds Small Cap Etf Small Cp Etf (VB)

View all positions for Glenmede Trust Company

Top funds holding Celldex Therapeutics

Wellington Management Company
Kynam Capital Management
BlackRock
FMR
Vanguard Group
Bellevue Group
State Street Corporation
Point72 Asset Management
Vanguard Capital Management
Commodore Capital
Geode Capital Management
Eventide Asset Management
Eversept Partners
Braidwell
Deep Track Capital

View all funds holding Celldex Therapeutics